Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study Day or who has not recovered (ie, ? Grade or at baseline) from adverse events due to agents administered more than weeks earlier. Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) =< days prior to registration or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier COHORT : Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier COHORT : Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to cycle day or who has not recovered (i.e. =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier. Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to registration or who has not recovered (i.e., =< grade or baseline) from adverse events due to agents administered > weeks prior Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Prior anti-cancer monoclonal antibody (mAb) within weeks prior to study Day or not recovered from an adverse event caused by mAbs administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Patient has received a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or baseline) from adverse events due to a previously administered agents Prior anti-cancer monoclonal antibody (mAb) within weeks prior to enrollment or who has not recovered from AEs due to mAb agents administered more than weeks earlier. Has received treatment with an anticancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study registration or who has not recovered (i.e. =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< Grade or at baseline) from adverse events due to agents administered more than weeks earlier. Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day , or targeted small molecule therapy within weeks prior to study day , or who has not recovered (i.e., ? grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Participants must not have had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or have not recovered (i.e. =< grade at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., ? grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., ? grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier. Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior, anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to Cycle /Day or who has not recovered (i.e., ? Grade or at baseline) from adverse events due to agents administered more than weeks earlier. Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier\r\n* Note: The use of denosumab is an exception to this criterion Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., ? grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti?cancer monoclonal antibody (mAb) within days prior to study day or who has not recovered (i.e., ? grade or at baseline) from adverse events due to agents administered more than days earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier. Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier. Prior anti-cancer monoclonal antibody (mAb) =< weeks prior to registration or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks prior to registration Has had a prior anti-cancer monoclonal antibody (mAb) within days prior to on-study date or who has not recovered (i.e., ? grade or baseline) from adverse events due to agents administered more than weeks earlier; (subjects with ? grade neuropathy are an exception to this criterion and may qualify for the study) Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) treatment within weeks prior to study day or who has not recovered (i.e., ? grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., ? grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or baseline) from adverse events (AEs) due to agents administered more than days earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or to baseline) from adverse events due to agents administered more than weeks earlier; note that denosumab for treatment for bone metastases is allowed Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Received an anti-cancer monoclonal antibody (mAb) within weeks prior to the first dose of study treatment or who has not recovered (i.e. ?Grade or baseline) from AEs due to agents administered more than weeks earlier. Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier; if a patient has progressive or stable disease to prior regimen, rituximab is allowed up to weeks prior to the initiation of study therapy Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Participants who have had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Patient has received a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or baseline) from adverse events due to a previously administered agents Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Prior anti-cancer monoclonal antibody (mAb) within weeks prior to the first dose of study drug or who has not recovered (i.e., =< grade or at baseline) from adverse events due to a previously administered agent Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) =< weeks prior to registration or who has not recovered (i.e., =< grade or at baseline level) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to such agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day (first day of SBRT treatment) or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (ie, =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier; toxicities that are disease related will not exclude patients Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Prior anti-cancer monoclonal antibody (mAb) within weeks prior to first dose of MK- or has not recovered (i.e., to =< grade or baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Patient has not recovered to grade - from adverse events due to prior chemotherapy, radiation, or biological cancer therapy (including monoclonal antibody [mAb]) Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study Day or who has not recovered (i.e., ? Grade or at baseline) from adverse events due to agents administered more than weeks earlier. Anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier. Has had a prior monoclonal antibody (mAb) within weeks prior to Study Day or who has not recovered (i.e. ? Grade or at baseline) from acute adverse events from prior mAb therapy NOTE: Subjects with ? Grade neuropathy or Grade alopecia are an exception to this criterion and may qualify for the study. Investigators should discuss individual cases with the Medical Monitor or Sponsor as needed; Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day , or targeted small molecule therapy within weeks prior to study day , or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier, with the exception of lymphopenia or asymptomatic aberrancies of sodium, amylase, lipase or alkaline phosphatase Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anticancer monoclonal antibody (mAb) within weeks prior to study Day or has not recovered (i.e. ? Grade or at Baseline) from adverse events (AEs) due to agents administered more than weeks earlier. Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade at baseline) from adverse events due to agents administered more than weeks earlier REGISTRATION TO TREATMENT (STEP ): Patient must not have received a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study registration or have not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier REGISTRATION TO TREATMENT (STEP ): Patient must not have received a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study registration or have not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to registration for protocol therapy or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day (excluding commercial or investigational anti-PD or anti-PD-L antibodies as single agents) or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier; patients who have autoimmune adverse events controlled by replacement therapy (i.e. hypothyroidism) due to previous treatment are eligible provided replacement therapy has been initiated and toxicity has returned to grade Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Prior anti-cancer therapy with a monoclonal antibody (mAb) =< weeks prior to registration OR failure to recover (to =< grade ) from adverse events (AE) attributable to agents received > weeks prior to registration Participants who have had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to cycle day or who have not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anticancer monoclonal antibody (mAb) within weeks prior to first dose study therapy or who has not recovered (i.e., Grade ? or at baseline) from AEs due to mAbs administered > weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) for direct anti-neoplastic treatment within weeks prior to the first dose of study drug ( weeks for nitrosoureas or mitomycin C) or who has not recovered (i.e., ? Grade or at Baseline) from adverse events (AEs) due to mAbs administered more than weeks earlier. Prior anti-cancer monoclonal antibody (mAb) therapy within weeks prior to Study Day , or not recovered from adverse events Prior anti-cancer therapy with a monoclonal antibody (mAb) within weeks prior to study day or not recovered from adverse events (improved to grade or less) due to mAbs administered more than weeks earlier Prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or has not recovered (i.e., =< grade or at baseline) for adverse events (AEs) due to agents administered > weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., >= grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Prior anti-cancer monoclonal antibody (mAb) within weeks prior to study Day or not recovered from adverse events due to agents administered more than weeks earlier Prior anti-cancer monoclonal antibody (mAb) for direct anti-neoplastic treatment within weeks prior to study Day or who has not recovered from adverse events due to agents administered more than weeks earlier Anti-cancer monoclonal antibody (mAb) within weeks prior to study Day or not recovered from adverse events due to agents administered more than weeks earlier Prior anti-cancer monoclonal antibody (mAb) therapy within weeks prior to study Day , or not recovered from adverse events due to agents administered more than weeks earlier Prior anti-cancer therapy with a monoclonal antibody (mAb) within weeks prior to study Day or not recovered from adverse events due to mAbs administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events (AE) due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior mAb within weeks prior to study Day or who has not recovered from adverse events due to agents administered more than weeks earlier. Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Patients who have had chemotherapy, radiotherapy, monoclonal antibody (mAb), or targeted small molecule therapy within weeks of study registration are not eligible; those who have not recovered from adverse events (grade or baseline) due to such agents administered more than weeks earlier are not eligible Prior anti-cancer monoclonal antibody (mAb) =< weeks prior to registration or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered >= weeks prior to registration Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior monoclonal antibody (mAb) within weeks prior to first dose of study drug in the study or who has not recovered (i.e., ? Grade or at baseline) from adverse events (AEs) due to agents administered more than weeks earlier. Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier Has had a prior anti-cancer monoclonal antibody (mAb) within weeks prior to study day or who has not recovered (i.e., =< grade or at baseline) from adverse events due to agents administered more than weeks earlier